Publication not explained
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
Featured Image
Read the Original
This page is a summary of: Economic Evidence Supports the Cost Savings of Sputum Eosinophil Counts to guide the treatment of pediatrics patients with Persistent Asthma: Implications for Clinical Practice Guidelines in Middle-Income Countries., Journal of Asthma, December 2023, Taylor & Francis,
DOI: 10.1080/02770903.2023.2300085.
You can read the full text:
Contributors
The following have contributed to this page
